Stem cell patch shows early promise in treating heart failure
American Heart Association Rapid Access Journal Report
- In a Phase I clinical trial, heart failure patients treated with patches made from their muscle cells showed improved exercise capacity and heart function after one year.
- Stem cell patch-based therapy may be a viable heart failure therapy and should be validated in larger clinical trials, researchers conclude.
Embargoed until 3 p.m. CT / 4 p.m. ET Wednesday, April 5, 2017
DALLAS, April 5, 2017 — Patching a damaged heart with a patient’s own muscle stem cells improves symptoms of heart failure, according to a Phase I clinical trial reported in Journal of the American Heart Association, the Open Access Journal of the American Heart Association/American Stroke Association.
In this new study, Japanese researchers made patches out of cells taken from the thigh muscles of patients with heart failure and surgically glued the patch onto the surface of the patients’ hearts. The 27 patients who received this treatment had limited exercise capacity and were not responding well to common heart failure treatments. The patients had no major complications from the procedure, and one year after receiving the patch, they showed improvements in their exercise capacity and heart function.
While therapies exist to treat heart failure, including drugs, implantable devices, and heart transplantation, these treatments are not good long-term options, and regenerating the damaged heart using a patient’s cells is a promising alternative, researchers noted.
The study suggests this cell patch may be a viable therapy to treat heart failure. Larger clinical trials are needed to validate the findings, researchers concluded.
Authors are Shigeru Miyagawa, M.D., Ph.D.; Keitaro Domae, M.D.; Yasushi Yoshikawa, M.D.; Satsuki Fukushima, M.D., Ph.D.; Teruya Nakamura, M.D., Ph.D.; Atsuhiro Saito, Ph.D.; Yasushi Sakata, M.D., Ph.D.; Seiki Hamada, M.D.; Koichi Toda, M.D.,Ph.D.; Kyongsun Pak; Masahiro Takeuchi, Ph.D.; and Yoshiki Sawa, M.D., Ph.D. Author disclosures are on the manuscript.
The Regenerative Medicine for Clinical Applications of Health and Labor Sciences Research and Japan Agency for Medical Research and Development supported this study.
- After April 5 view the manuscript online.
- Follow AHA/ASA news on Twitter @HeartNews
- For updates and new science from JAHA, follow @JAHA_AHA
Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association’s policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding.
For Media Inquiries and AHA/ASA Spokesperson Perspective: (214) 706-1173
Akeem Ranmal: (214) 706-1755; firstname.lastname@example.org
For Public Inquiries: (800)-AHA-USA1 (242-8721)
Life is why, science is how . . . we help people live longer, healthier lives.